Cleveland Clinic, 9500 Euclid Avenue, NE50, Cleveland, Ohio 44195, USA.
J Clin Endocrinol Metab. 2012 Nov;97(11):E2179-87. doi: 10.1210/jc.2012-1991. Epub 2012 Sep 7.
Germline mutations in PTEN are associated with phosphatase and tensin homolog deleted on chromosome 10 (PTEN) hamartoma tumor syndrome including Cowden syndrome (CS) and Cowden-like syndrome (CSL) that predisposes to high risks of benign and malignant tumors of thyroid and breast.
The objective of the study was to analyze the subcellular pattern of phosphorylated (P)-AKT expression in nonmedullary thyroid cancers from PTEN hamartoma tumor syndrome patients and to investigate whether the lack of PTEN in the nucleus and/or lack of proper PTEN function in the nucleus affect(s) nuclear AKT activity in CS patients.
In all, 664 patients with CS/CSL were screened for PTEN germline mutations and nonmedullary thyroid cancers. Twenty-two patients who have both pathogenic PTEN germline mutations and nonmedullary thyroid cancers were selected. Thyroid samples from these patients were stained for PTEN and P-AKT. In our in vitro study, PTEN was knocked down or overexpressed in both thyroid cancer cells and breast cancer cells, and nuclear P-AKT was compared with the control.
Loss of PTEN protein was found in thyroid adenomas and carcinomas from all 22 (100%) PTEN(Mut+) CS/CSL patients. AKT activation was identified in 17 of 22 (77.3%) thyroid adenoma/carcinoma specimens, and most patients (63.7%) have activated nuclear AKT. Knockdown of PTEN in cells containing wild-type PTEN enhanced nuclear P-AKT, whereas expression of wild-type PTEN, but not phosphatase-dead mutants (C124S or G129E), markedly reduced nuclear P-AKT in PTEN null cells. We also showed that in breast cancer but not thyroid cancer cells, PTEN suppresses nuclear P-AKT mainly through decreasing P-AKT nuclear translocation by reducing the PIP3/P-AKT reservoir in the cytoplasm. In thyroid cancer cells, PTEN suppresses phosphorylation of AKT already resident in the nucleus.
PTEN is necessary and sufficient for inhibiting AKT activation in the nucleus through its intact lipid phosphatase activity and proper subcellular localization.
PTEN 种系突变与磷酸酶和张力蛋白同源物缺失于第 10 号染色体(PTEN)错构瘤肿瘤综合征相关,包括考登综合征(CS)和考登样综合征(CSL),使甲状腺和乳腺的良性和恶性肿瘤风险增加。
本研究旨在分析 PTEN 错构瘤肿瘤综合征患者的非髓样甲状腺癌中磷酸化(P)-AKT 表达的亚细胞模式,并研究核内 PTEN 缺失和/或核内适当的 PTEN 功能缺失是否影响 CS 患者的核 AKT 活性。
共筛选了 664 例 CS/CSL 患者的 PTEN 种系突变和非髓样甲状腺癌。选择了 22 例同时患有致病性 PTEN 种系突变和非髓样甲状腺癌的患者。对这些患者的甲状腺样本进行了 PTEN 和 P-AKT 染色。在我们的体外研究中,在甲状腺癌细胞和乳腺癌细胞中敲低或过表达了 PTEN,比较了核内 P-AKT 与对照。
22 例(100%)PTEN(Mut+)CS/CSL 患者的甲状腺腺瘤和癌中均发现 PTEN 蛋白缺失。在 22 例甲状腺腺瘤/癌标本中,有 17 例(77.3%)发现 AKT 激活,大多数患者(63.7%)有激活的核 AKT。在含有野生型 PTEN 的细胞中敲低 PTEN 增强了核内 P-AKT,而表达野生型 PTEN,但不是磷酸酶失活突变体(C124S 或 G129E),则显著降低了 PTEN 缺失细胞中的核 P-AKT。我们还表明,在乳腺癌细胞中,但不是甲状腺癌细胞中,PTEN 通过减少细胞质中 PIP3/P-AKT 库来减少 P-AKT 核转位,从而主要抑制核内 P-AKT。在甲状腺癌细胞中,PTEN 通过抑制已存在于核内的 AKT 的磷酸化来抑制 AKT 的激活。
通过其完整的脂质磷酸酶活性和适当的亚细胞定位,PTEN 是抑制核内 AKT 激活所必需和充分的。